TVRD
$3.64
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need in the United States. The com...
Recent News
We're Keeping An Eye On Tvardi Therapeutics' (NASDAQ:TVRD) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Tvardi (TVRD) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Tvardi (TVRD) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Tvardi: Q3 Earnings Snapshot
SUGAR LAND, Texas (AP) — Tvardi Therapeutics, Inc. TVRD) on Thursday reported a loss of $5.5 million in its third quarter. On a per-share basis, the Sugar Land, Texas-based company said it had a loss of 59 cents.
Here's Why Tvardi (TVRD) Is a Great 'Buy the Bottom' Stock Now
Tvardi (TVRD) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Down 83.0% in 4 Weeks, Here's Why Tvardi (TVRD) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Tvardi (TVRD) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.